Atypical hemolytic uremic syndrome in children: Complement mutations and clinical characteristics

Pediatric Nephrology

Volumn 27, Issue 8, 2012, Pages 1283-1291

  Geerdink, Lianne M ^a   Westra, Dineke ^a   Van Wijk, Joanna A E ^b   Dorresteijn, Eiske M ^c   Lilien, Marc R ^d   Davin, Jean Claude ^e,f   Kömhoff, Martin ^g   Van Hoeck, Koen ^h   Van Der Vlugt, Amerins ⁱ   Van Den Heuvel, Lambertus P ^a,j   Van De Kar, Nicole C A J ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^c SOPHIA CHILDREN S HOSPITAL   (Netherlands)

^d UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^e UNIVERSITY OF AMSTERDAM   (Netherlands)

^f FREE UNIVERSITY OF BRUSSELS   (Belgium)

^g UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^h ANTWERP UNIVERSITY HOSPITAL   (Belgium)

ⁱ ST ANTONIUS HOSPITAL   (Netherlands)

^j UNIVERSITY HOSPITALS LEUVEN   (Belgium)

more..

Author keywords

Atypical HUS; Clinical outcome; Complement regulation; Dialysis; Plasma therapy; Transplantation

Indexed keywords

ALTERNATIVE COMPLEMENT PATHWAY C3 C5 CONVERTASE; AUTOANTIBODY; COMPLEMENT; COMPLEMENT COMPONENT C3; COMPLEMENT FACTOR H; COMPLEMENT FACTOR H AUTOANTIBODY; COMPLEMENT FACTOR H RELATED PROTEIN 1; COMPLEMENT FACTOR H RELATED PROTEIN 3; COMPLEMENT FACTOR I; MEMBRANE COFACTOR PROTEIN; UNCLASSIFIED DRUG;

ARTICLE; CHILD; CHILDHOOD DISEASE; CLINICAL ARTICLE; COMPLEMENT BLOOD LEVEL; DIARRHEA; DISEASE COURSE; FEMALE; GENE MUTATION; GENETIC ASSOCIATION; HEMOLYTIC UREMIC SYNDROME; HUMAN; INFANT; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; MALE; NEWBORN; PRESCHOOL CHILD; PRIORITY JOURNAL; PROGNOSIS; RELAPSE; RETROSPECTIVE STUDY; SCHOOL CHILD; TREATMENT OUTCOME;

AGE OF ONSET; AUTOANTIBODIES; AUTOANTIGENS; CHILD; CHILD, PRESCHOOL; COMPLEMENT SYSTEM PROTEINS; DNA MUTATIONAL ANALYSIS; FEMALE; HEMOLYTIC-UREMIC SYNDROME; HUMANS; INFANT; INFANT, NEWBORN; MALE; MUTATION; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 84863985862     PISSN: 0931041X     EISSN: 1432198X     Source Type: Journal    
DOI: 10.1007/s00467-012-2131-y     Document Type: Article

References (29)

1. Ruggenenti P, Noris M, Remuzzi G (2001) Thrombotic micro-angiopathy, hemolytic uremic syndrome, and thrombotic thrombo-cytopenic purpura. Kidney Int 60:831-846 (Pubitemid 34205784)
2. Noris M, Remuzzi G (2009) Atypical hemolytic-uremic syndrome. N Engl J Med 361:1676-1687
3. Sellier-Leclerc AL, Fremeaux-Bacchi V, Dragon-Durey MA, Macher MA, Niaudet P, Guest G, Boudailliez B, Bouissou F, Deschenes G, Gie S, Tsimaratos M, Fischbach M, Morin D, Nivet H, Alberti C, Loirat C (2007) Differential impact of complement mutations on clinical characteristics in atypical hemolytic uremic syndrome. J Am Soc Nephrol 18:2392-2400 (Pubitemid 47203855)
4. Sharma AP, Greenberg CR, Prasad AN, Prasad C (2007) Hemo-lytic uremic syndrome (HUS) secondary to cobalamin C (cblC) disorder. Pediatr Nephrol 22:2097-2103 (Pubitemid 350090717)
5. Caprioli J, Noris M, Brioschi S, Pianetti G, Castelletti F, Bettina-glio P, Mele C, Bresin E, Cassis L, Gamba S, Porrati F, Bucchioni S, Monteferrante G, Fang CJ, Liszewski MK, Kavanagh D, Atkinson JP, Remuzzi G (2006) Genetics of HUS: the impact of MCP, CFH, and IF mutations on clinical presentation, response to treatment, and outcome. Blood 108:1267-1279 (Pubitemid 44232024)
6. Noris M, Caprioli J, Bresin E, Mossali C, Pianetti G, Gamba S, Daina E, Fenili C, Castelletti F, Sorosina A, Piras R, Donadelli R, Maranta R, van der Meer I, Conway EM, Zipfel PF, Goodship TH, Remuzzi G (2010) Relative role of genetic complement abnormalities in sporadic and familial aHUS and their impact on clinical phenotype. Clin J Am Soc Nephrol 5:1844-1859
7. Richards A, Kemp EJ, Liszewski MK, Goodship JA, Lampe AK, Decorte R, Müslümanoǧlu MH, Kavukcu S, Filler G, Pirson Y, Wen LS, Atkinson JP, Goodship TH (2003) Mutations in human complement regulator, membrane cofactor protein (CD46), predispose to development of familial hemolytic uremic syndrome. Proc Natl Acad Sci USA 100:12966-12971 (Pubitemid 37340009)
8. Fremeaux-Bacchi V, Moulton EA, Kavanagh D, Dragon-Durey MA, Blouin J, Caudy A, Arzouk N, Cleper R, Francois M, Guest G, Pourrat J, Seligman R, Fridman WH, Loirat C, Atkinson JP (2006) Genetic and functional analyses of membrane cofactor protein (CD46) mutations in atypical hemolytic uremic syndrome. J Am Soc Nephrol 17:2017-2025 (Pubitemid 44036186)
9. Westra D, Volokhina E, van der Heijden E, Vos A, Huigen M, Jansen J, van Kaauwen E, van der Velden T, van de Kar N, van den Heuvel L (2010) Genetic disorders in complement (regulating) genes in patients with atypical haemolytic uraemic syndrome (aHUS). Nephrol Dial Transplant 25:2195-2202
10. Fremeaux-Bacchi V, Dragon-Durey MA, Blouin J, Vigneau C, Kuypers D, Boudailliez B, Loirat C, Rondeau E, Fridman WH (2004) Complement factor I: a susceptibility gene for atypical haemolytic uraemic syndrome. J Med Genet 41:e84
11. Kavanagh D, Kemp EJ, Mayland E, Winney RJ, Duffield JS, Warwick G, Richards A, Ward R, Goodship JA, Goodship TH (2005) Mutations in complement factor I predispose to development of atypical hemo-lytic uremic syndrome. J Am Soc Nephrol 16:2150-2055
12. Goicoechea de Jorge E, Harris CL, Esparza-Gordillo J, Carreras L, Arranz EA, Garrido CA, López-Trascasa M, Sánchez-Corral P, Morgan BP, Rodríguez de Córdoba S (2007) Gain-of-function mutations in complement factor B are associated with atypical hemolytic ure-mic syndrome. Proc Natl Acad Sci USA 104:240-245 (Pubitemid 46068016)
13. Caprioli J, Remuzzi G (2007) Complement hyperactivation may cause atypical haemolytic uraemic syndrome-gain-of-function mutations in factor B. Nephrol Dial Transplant 22:2452-2454 (Pubitemid 47365505)
14. Frémeaux-Bacchi V, Miller EC, Liszewski MK, Strain L, Blouin J, Brown AL, Moghal N, Kaplan BS, Weiss RA, Lhotta K, Kapur G, Mattoo T, Nivet H, Wong W, Gie S, Hurault de Ligny B, Fischbach M, Gupta R, Hauhart R, Meunier V, Loirat C, Dragon-Durey MA, Fridman WH, Janssen BJ, Goodship TH, Atkinson JP (2008) Mutations in complement C3 predispose to development of atypical hemolytic uremic syndrome. Blood 112:4948-4952
15. Dragon-Durey MA, Loirat C, Cloarec S, Macher MA, Blouin J, Nivet H, Weiss L, Fridman WH, Frémeaux-Bacchi V (2005) AntiFactor H autoantibodies associated with atypical hemolytic uremic syndrome. J Am Soc Nephrol 16:555-563 (Pubitemid 41725154)
16. Zipfel PF, Edey M, Heinen S, Józsi M, Richter H, Misselwitz J, Hoppe B, Routledge D, Strain L, Hughes AE, Goodship JA, Licht C, Goodship TH, Skerka C (2007) Deletion of complement factor H-related genes CFHR1 and CFHR3 is associated with atypical hemolytic uremic syndrome. PLoS Genet 3:e41
17. Józsi M, Licht C, Strobel S, Zipfel SL, Richter H, Heinen S, Zipfel PF, Skerka C (2008) Factor H autoantibodies in atypical hemolytic uremic syndrome correlate with CFHR1/CFHR3 deficiency. Blood 111:1512-1514 (Pubitemid 351213440)
18. Moore I, Strain L, Pappworth I, Kavanagh D, Barlow PN, Herbert AP, Schmidt CQ, Staniforth SJ, Holmes LV, Ward R, Morgan L, Goodship TH, Marchbank KJ (2010) Association of factor H autoantibodies with deletions of CFHR1, CFHR3, CFHR4, and with mutations in CFH, CFI, CD46, and C3 in patients with atypical hemolytic uremic syndrome. Blood 115:379-387
19. Delvaeye M, Noris M, De Vriese A, Esmon CT, Esmon NL, Ferrell G, Del-Favero J, Plaisance S, Claes B, Lambrechts D, Zoja C, Remuzzi G, Conway EM (2009) Thrombomodulin mutations in atypical hemolytic-uremic syndrome. N Engl J Med 361:345-357
20. Józsi M, Strobel S, Dahse HM, Liu WS, Hoyer PF, Oppermann M, Skerka C, Zipfel PF (2007) Anti factor H autoantibodies block C-terminal recognition function of factor H in hemolytic uremic syndrome. Blood 110:1516-1518 (Pubitemid 47443967)
21. Bouts AH, Roofthooft MT, Salomons GS, Davin JC (2010) CD46-associated atypical hemolytic uremic syndrome with uncommon course caused by cblC deficiency. Pediatr Nephrol 25:2547-2548
22. Olie KH, Goodship TH, Verlaak R, Florquin S, Groothoff JW, Strain L, Weening JJ, Davin JC (2005) Posttransplantation cytomegalovirus-induced recurrence of atypical hemolytic uremic syndrome associated with a factor H mutation: successful treatment with intensive plasma exchanges and ganciclovir. Am J Kidney Dis 45:e12-e15 (Pubitemid 40038036)
23. Davin JC, Gracchi V, Bouts A, Groothoff J, Strain L, Goodship T (2010) Maintenance of kidney function following treatment with eculizumab and discontinuation of plasma exchange after a third kidney transplant for atypical hemolytic uremic syndrome associated with a CFH mutation. Am J Kidney Dis 55:708-711
24. Weitz M, Amon O, Bassler D, Koenigsrainer A, Nadalin S (2011) Prophylactic eculizumab prior to kidney transplantation for atypical hemolytic uremic syndrome. Pediatr Nephrol 26:1325-1329
25. Ariceta G, Besbas N, Johnson S, Karpman D, Landau D, Licht C, Loirat C, Pecoraro C, Taylor CM, Van de Kar N, Vandewalle J, Zimmerhackl LB (2009) Guideline for the investigation and initial therapy of diarrhea-negative hemolytic uremic syndrome. Pediatr Nephrol 24:687-696
26. Bresin E, Daina E, Noris M, Castelletti F, Stefanov R, Hill P, Goodship TH, Remuzzi G (2006) Outcome of renal transplantation in patients with non-Shiga toxin-associated hemolytic uremic syndrome: prognostic significance of genetic background. Clin J Am Soc Nephrol 1:88-99
27. Noris M, Remuzzi G (2010) Thrombotic microangiopathy after kidney transplantation. Am J Transplant 10:1517-1523
28. Davin JC, Strain L, Goodship TH (2008) Plasma therapy in atypical haemolytic uremic syndrome: lessons from a family with a factor H mutation. Pediatr Nephrol 23:1517-1521
29. Roumenina LT, Frimat M, Miller EC, Provot F, Dragon-Durey MA, Bordereau P, Bigot S, Hue C, Satchell SC, Mathieson PW, Mousson C, Noel C, Santes-Fridman C, Halbwachs-Mecarelli L, Atkinson JP, Liomet A, Fremeaux-Bacchi V (2012) A prevalent C3 mutation in a HUS patients causes a direct C3 convertase gain-of-function. Blood. doi:10.1182/blood-2011-10-383281